Abstract
Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.
| Original language | English |
|---|---|
| Journal | Clinical Infectious Diseases |
| Volume | 37 |
| Issue number | SUPPL. 2 |
| DOIs | |
| State | Published - Sep 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. / Baum, Marianna K.; Campa, Adriana; Lai, Shengan; Lai, Hong; Page, John.
In: Clinical Infectious Diseases, Vol. 37, No. SUPPL. 2, 01.09.2003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Zinc status in human immunodeficiency virus type 1 infection and illicit drug use
AU - Baum, Marianna K.
AU - Campa, Adriana
AU - Lai, Shengan
AU - Lai, Hong
AU - Page, John
PY - 2003/9/1
Y1 - 2003/9/1
N2 - Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.
AB - Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.
UR - http://www.scopus.com/inward/record.url?scp=0042761942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042761942&partnerID=8YFLogxK
U2 - 10.1086/375875
DO - 10.1086/375875
M3 - Article
C2 - 12942385
AN - SCOPUS:0042761942
VL - 37
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 2
ER -